No Recovery, No Fee! Rosen Law Firm Explains Securities Class Action Lawsuits

Many investors have heard of 'securities class action lawsuits,' but may not truly understand what they are—or how they can help. Today, we’ve compiled answers to several of the most frequently asked questions to help you quickly grasp the essentials👇 1️⃣ What is a securities class action lawsuit? 👉 In simple terms, it’s a legal mechanism whereby investors collectively sue a company for damages after suffering losses due to the company’s false statements, financial fraud, or materially misleading disclosures—actions that caused the stock price to drop. 2️⃣ What is the 'class period'? 👉 It refers to the timeframe during which the stock price was artificially inflated by false or misleading information. Only investors who purchased shares—and incurred losses—during this period are eligible to join the lawsuit and receive compensation. 3️⃣ What is a 'lead plaintiff'? 👉 The lead plaintiff serves as the 'representative leader' appointed by the court to act on behalf of all injured investors in guiding the case. While typically the investor with the largest financial loss, the ultimate recovery and settlement benefits all qualified members of the class. 4️⃣ Advantages of securities class action lawsuits ✔️ Investors avoid filing individual lawsuits—saving time and effort ✔️ Contingency-fee basis: no upfront legal costs for plaintiffs ✔️ Even relatively small losses can be recovered collectively

Globally Recognized Law Firm ROSEN Alerts Interface, Inc. Investors to TILE Securities Class Action Lawsuit

The complaint alleges that defendants made false and/or misleading statements, and/or failed to disclose, throughout the class period: (1) that Interface lacked adequate disclosure controls and procedures and internal controls over financial reporting; (2) as a result, among other things, Interface had artificially inflated its revenue and earnings per share (EPS) for 2015 and 2016; (3) since at least November 2017, Interface and certain of its employees had been under investigation by the U.S. Securities and Exchange Commission (SEC), had obstructed the SEC’s investigation, and had downplayed the true scope of Interface’s misconduct and liability related to the SEC investigation; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times. The complaint further alleges that investors suffered losses when the truth entered the market. The law firm has already filed the class action lawsuit. If you wish to serve as lead plaintiff, you must apply to the court no later than January 11, 2021. The lead plaintiff acts as the representative party on behalf of all other class members in directing the litigation. If you wish to join the lawsuit, please register at http://www.rosenlegal.com/cases-register-1788.html. To discuss your rights or interests in this class action, please contact attorney Phillip Kim toll-free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com. The proposed class has not yet been certified. Until certification occurs, counsel will not provide legal services to individuals except upon retention. Individuals may choose to retain their own counsel or remain passive class members without taking any action at this time. An investor’s share of any future recovery is not affected by whether or not they serve as lead plaintiff. Stay updated by following us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, Twitter: https://twitter.com/rosen_firm, or Facebook: https://www.facebook.com/rosenlawfirm/

Robbins LLP Urges Chemours Investors to Join Class Action Over Opteon Demand Allegations

Oct 22, 2026

Robbins LLP urges Chemours investors with losses between February and August 2026 to contact the firm regarding a class action lawsuit alleging overstated Opteon demand led to unreliable financial guidance and stock price drops.

The Globe and Mail

2026-10-09

Chemours Company Faces Securities Fraud Class Action Over Opteon Demand Claims

2026-10-11

Chemours Faces Securities Lawsuit Over Disclosures and Guidance

2026-10-11

Chemours Company Faces Class Action Lawsuit Alleging Investor Harm

2026-10-12

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.

2026-10-12

Class Action Lawsuit Filed Against Chemours Over Overstated Demand and Lowered 2026 Guidance